{"id":59,"date":"2022-11-28T20:52:54","date_gmt":"2022-11-28T20:52:54","guid":{"rendered":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo2\/?page_id=59"},"modified":"2025-12-16T12:21:51","modified_gmt":"2025-12-16T12:21:51","slug":"how-voxzogo-works","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/","title":{"rendered":"How VOXZOGO Works"},"content":{"rendered":"
\n
\n
\n \n
\n

VOXZOGO is the only FDA-approved therapy indicated for children from birth until growth plates close that targets the underlying cause of achondroplasia1-3<\/sup><\/h1>\n <\/div>\n\n
\n

VOXZOGO targets overactive FGFR3 signaling in achondroplasia by mimicking the body\u2019s natural CNP to promote endochondral bone growth, but only while growth plates remain open.1<\/sup><\/h3>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
\n
\n
\n \n
\n
\n
\n\t\t\t \"How\t\t\t<\/div>\n\t\t\t
\n\t\t\t \"How\t\t\t<\/div>\n <\/div>\n

This graphic is an illustration of the cell signaling imbalance in achondroplasia and how VOXZOGO is designed to improve the balance. This graphic is not to scale and does not reflect a percentage growth.<\/p>\n

CNP,<\/strong> C-type natriuretic peptide; FGFR3,<\/strong> fibroblast growth factor receptor 3.<\/p>\n<\/figcaption>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t
\n
\n\t\t\t Play<\/a>\n\t\t <\/div>\n \n \n \n\t\t <\/div>\n \n
\n

Watch how VOXZOGO targets overactive FGFR3 signaling to promote bone growth1<\/sup><\/h3>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n<\/div>\n\n
\n
\n
\n \n
\n

Children with achondroplasia experience the greatest potential for growth early in life4*<\/sup><\/h2>\n


\nBy 2 years old,<\/strong> children with achondroplasia achieve more than half of their adult height4*<\/sup><\/strong><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n
\n \n
\n
\n
\n\t\t\t \"Timeline\t\t\t<\/div>\n\t\t\t
\n\t\t\t \"Timeline\t\t\t<\/div>\n <\/div>\n

*Based on stature-for-age data (birth to 18 years old) from CLARITY, an achondroplasia natural history study, comprised of measurements from 549 males and 502 females with achondroplasia.4<\/sup><\/p>\n<\/figcaption>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n
\n \n
\n

International consensus guidelines provide a practical framework for clinicians treating with VOXZOGO7<\/sup><\/h2>\n

Developed by 16 international experts (14 clinical experts, 2 patient representatives; 5 from the US). BioMarin provided funding for this project, including to the participants. BioMarin was not involved in the selection of the guidelines development group, defining the guidelines scope, the voting process, analysis of the results, or preparation of the submitted manuscript. Please see Acknowledgements section of publication for additional detail.7<\/sup><\/p>\n


\n<\/sup>The guidelines provide recommendations across the treatment pathway, from before starting treatment to ongoing monitoring7<\/sup>:<\/span><\/h3>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t
\n \n \n \n \n
\n
\n
\n \"\" <\/div>\n
\n \"\" <\/div>\n <\/div>\n <\/figure>\n <\/div>\n \n
\n \n \n \n \n
\n
\n
\n \"\" <\/div>\n
\n \"\" <\/div>\n <\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n
\n
\n \n
\n

 <\/p>\n

These are select sections of a few recommendations for the use of VOXZOGO (vosoritide) in clinical practice. The guidelines publication should be reviewed in its entirety along with the VOXZOGO Prescribing Information.1,7<\/sup><\/p>\n

 <\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n
\n \n
\n
\n
\n\t\t\t \"\"\t\t\t<\/div>\n\t\t\t
\n\t\t\t \"\"\t\t\t<\/div>\n <\/div>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\n
\n
\n
\n \n
\n

Learn More<\/a><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n\t\t
\n\t\t \t\t\t

References:\n<\/h4>\n\t\t\t\t\t\t
    \n
  1. VOXZOGO [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2024.\n<\/span><\/li>\n
  2. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet<\/em>. 2007;370(9582):162-172.\n<\/span><\/li>\n
  3. Savarirayan R, Ireland P, Irving M, et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol<\/em>. 2022;18(3):173-189.\n<\/span><\/li>\n
  4. Savarirayan R, Hoover-Fong J, Ozono K, et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol<\/em>. 2025;21(5):314-324.\n<\/span><\/li>\n
  5. Mackie EJ, Tatarczuch L, Mirams M. The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. J Endocrinol<\/em>. 2011;211(2):109-121.\n<\/span><\/li>\n
  6. Kvist O, Dallora AL, Nilsson O, et al. A cross-sectional magnetic resonance imaging study of factors influencing growth plate closure in adolescents and young adults. Acta Paediatr<\/em>. 2021;110(4):1249-1256.\n<\/span><\/li>\n
  7. Savarirayan R, Hoover-Fong J, Ozono K, et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol.<\/em> 2025;21(5):314-324.\n<\/span><\/li>\n <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-59","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nHow VOXZOGO\u00ae Works | VOXZOGO\u00ae (vosoritide) HCP<\/title>\n<meta name=\"description\" content=\"Learn more about how VOXZOGO works for your infant and children patients with achondroplasia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How VOXZOGO\u00ae Works | VOXZOGO\u00ae (vosoritide) HCP\" \/>\n<meta property=\"og:description\" content=\"Learn more about how VOXZOGO works for your infant and children patients with achondroplasia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Voxzogo HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-16T12:21:51+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/\",\"name\":\"How VOXZOGO\u00ae Works | VOXZOGO\u00ae (vosoritide) HCP\",\"isPartOf\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/#website\"},\"datePublished\":\"2022-11-28T20:52:54+00:00\",\"dateModified\":\"2025-12-16T12:21:51+00:00\",\"description\":\"Learn more about how VOXZOGO works for your infant and children patients with achondroplasia.\",\"breadcrumb\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How VOXZOGO Works\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/#website\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/\",\"name\":\"BioMarin Voxzogo HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How VOXZOGO\u00ae Works | VOXZOGO\u00ae (vosoritide) HCP","description":"Learn more about how VOXZOGO works for your infant and children patients with achondroplasia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/","og_locale":"en_US","og_type":"article","og_title":"How VOXZOGO\u00ae Works | VOXZOGO\u00ae (vosoritide) HCP","og_description":"Learn more about how VOXZOGO works for your infant and children patients with achondroplasia.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/","og_site_name":"BioMarin Voxzogo HCP EN-US","article_modified_time":"2025-12-16T12:21:51+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/","url":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/","name":"How VOXZOGO\u00ae Works | VOXZOGO\u00ae (vosoritide) HCP","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/#website"},"datePublished":"2022-11-28T20:52:54+00:00","dateModified":"2025-12-16T12:21:51+00:00","description":"Learn more about how VOXZOGO works for your infant and children patients with achondroplasia.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/how-voxzogo-works\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/"},{"@type":"ListItem","position":2,"name":"How VOXZOGO Works"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/","name":"BioMarin Voxzogo HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/pages\/59","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/comments?post=59"}],"version-history":[{"count":498,"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/pages\/59\/revisions"}],"predecessor-version":[{"id":5486,"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/pages\/59\/revisions\/5486"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/voxzogo\/wp-json\/wp\/v2\/media?parent=59"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}